(Q33545458)

English

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

based on heuristic

inferred from title

Tore Wentzel-Larsen

3

object named as

Tore Wentzel-Larsen

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

Erik Johnsen

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Rune A Kroken

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Hugo A Jørgensen

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

publication date

24 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

24 March 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/1471-244x-10-26

0 references

The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Effectiveness of second generation antipsychotics: a systematic review of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

31 October 2018

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

The Mount Sinai conference on the pharmacotherapy of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Assessing substance use disorder in persons with severe mental illness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

21 June 2018

The case for practical clinical trials in psychiatry

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

31 October 2018

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

31 October 2018

Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2851682

31 October 2018

Mixed-Effects Models in Sand S-PLUS

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Selection Bias in Clinical Trials With Antipsychotics

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-26

21 January 2018

Dose equivalence of the antipsychotic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/20334680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A depression rating scale for schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20334680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20334680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20334680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Treatment guidelines for non-schizophrenic psychotic disorders?]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20334680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-244X-10-26

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-244x-10-26

9 September 2019

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33545458&oldid=1870581403"